8 July, 2024Myricx Bio announces £90m ($114m) Series A financing to advance its novel NMTi-ADC therapeutics into clinical development
2 July, 2024Mission Therapeutics awarded $5.2m from The Michael J. Fox Foundation and Parkinson’s UK to advance potential disease-modifying treatment MTX325
26 June, 2024Crescendo Biologics announces that Zai Lab has initiated a global Phase 2 clinical trial evaluating ZL-1102 (Humabody®, CB001) as a topical treatment for psoriasis